"인체 삽입용 의료용구" 국가연구개발지원사업 참여 및 종료. 

당사 (주)마이크로사이언스테크 (MST·회장 문웅식·www.BioCleanAct.com·브랜드명:바이오크린액트™) 중앙연구소는 

지역특화산업육성+(R&D) 지역스타기업육성사업에 선정되어 2년간 국책 연구개발사업을 수행함.(2023~2024)

[천연물 합성 TPU 기반의 항균 컴파운드를 활용한 혈류감염 방지용 5Fr, 325psi급 고내압 말초삽입형 중심정맥카테터 개발,PICC]

당사의 천연물기반 항균컴파운드를 적용한 Infection free 인체 삽입용 PICC 제품상업화 국책연구개발과제를 수행, 성공함.

또한 당사의 천연항균신소재(세균2차감염방지용)로 

일본의 구라레그룹메디칼본부, 독일 지멘스핼스케어, 삼성전자 메디칼사업부, 세운메디칼등과도

메디칼디바이스분야에 공동 연구 개발 사례등 들이 있음

**Participation in the National R&D Project for "Implantable Medical Devices"**  

MST(KOREA) CO., LTD. (MST, Chairman: Woongsig Moon, [www.BioCleanAct.com](http://www.BioCleanAct.com), Brand: BioCleanAct™) Central Research Institute was selected for the **Regional Specialized Industry Promotion + (R&D) Regional Star Enterprise Promotion Project** and has been conducting a **national research and development project for two years (2023–2024).**  

**[Development of a high-pressure 5Fr, 325psi peripherally inserted central catheter (PICC) for the prevention of bloodstream infections using a natural compound-based TPU antibacterial compound]**  

MST successfully carried out and completed a **national R&D commercialization project** for an **Infection-free implantable PICC** incorporating its **natural compound-based antibacterial material.**  

Furthermore, MST's **new natural antibacterial material** (for secondary bacterial infection prevention) has been the subject of joint research and development in the medical device sector with:  

- Kuraray Group Medical Division (Japan)  

- Siemens Healthineers (Germany)  

- Samsung Electronics Medical Division  

- Sewoon Medical, and others.